First, do no harm: risk of secondary cancer after breast cancer treatment. Read more about First, do no harm: risk of secondary cancer after breast cancer treatment.
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Read more about Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Read more about Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
Systemic considerations for the surgical treatment of spinal metastatic disease: a scoping literature review. Read more about Systemic considerations for the surgical treatment of spinal metastatic disease: a scoping literature review.
Survivorship after neoadjuvant chemotherapy - Authors' reply. Read more about Survivorship after neoadjuvant chemotherapy - Authors' reply.
Immune checkpoint inhibitors and timing of administration. Read more about Immune checkpoint inhibitors and timing of administration.
Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose. Read more about Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose.
Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Read more about Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.
Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Read more about Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Read more about Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
